Aptuit Appoints New CEO - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Aptuit Appoints New CEO



Untitled Document

Aptuit, a provider of outsourced services in the early development space, has appointed Jonathan Goldman, MD, as the company’s new CEO. Goldman joins the company after working at ICON Clinical Research.

Goldman was most recently executive vice president, global strategic and business development at ICON and a member of the senior leadership team. Previously, his roles at ICON included executive VP, operations, strategic programs and chief medical officer, ICON Medical Imaging.

Before joining ICON, Goldman served for seven years as the chief medical officer of POINT Biomedical, a US-based biopharmaceutical company that discovered and developed microsphere technologies and drugs. In addition, he has held academic positions at the University of California since 2000, most recently as associate clinical professor of medicine in the Division of Cardiology.

Source: Aptuit

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here